These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Clinical evaluation of amikacin in severe infections with hematological malignant diseases (author's transl)]. Hotta T; Hirabayashi N; Shimizu K; Utsumi M; Katoh T; Maeda H; Hirano A; Ohnishi K; Murate T; Yamada H Jpn J Antibiot; 1981 Nov; 34(11):1457-64. PubMed ID: 7334580 [TBL] [Abstract][Full Text] [Related]
5. Effect of 'high-dose' amikacin in children. Kumor KM; McDonald JM; Lietman PS Dev Pharmacol Ther; 1984; 7(6):368-76. PubMed ID: 6518944 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of amikacin in infants and pre-school children. Kafetzis DA; Sinaniotis CA; Papadatos CJ; Kosmidis J Acta Paediatr Scand; 1979 May; 68(3):419-22. PubMed ID: 443042 [TBL] [Abstract][Full Text] [Related]
7. Disposition kinetics of amikacin in patients with renal impairment after intramuscular administration. Lanao JM; Dominguez-Gil A; Tabernero JM; Molina HD Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):271-5. PubMed ID: 7107075 [TBL] [Abstract][Full Text] [Related]
8. Clinical application of amikacin dosage based upon lean body mass in patients with different renal function. Wagenvoort JH; Fieren MW; Goessens WH; Michel MF Chemotherapy; 1984; 30(2):69-75. PubMed ID: 6697814 [TBL] [Abstract][Full Text] [Related]
9. [Control of serum levels of tobramycin and amikacin during clinical routine treatment conditions (author's transl)]. Stark GB; Eiermann T; Langmaack H; Daschner F Dtsch Med Wochenschr; 1982 Aug; 107(31-32):1182-4. PubMed ID: 7105995 [TBL] [Abstract][Full Text] [Related]
10. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Zaske DE; Cipolle RJ; Strate RJ Surgery; 1980 Feb; 87(2):164-9. PubMed ID: 7355388 [TBL] [Abstract][Full Text] [Related]
11. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes. Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of intravenous amikacin after rapid and slow infusion with special reference to hemodialysis. Pechere JC; Dugal R; Pechere MM Eur J Drug Metab Pharmacokinet; 1979; 4(1):49-56. PubMed ID: 467467 [TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of amikacin in dogs. Baggot JD; Ling GV; Chatfield RC Am J Vet Res; 1985 Aug; 46(8):1793-6. PubMed ID: 4037511 [TBL] [Abstract][Full Text] [Related]
17. Increase of amikacin half-life during therapy in patients with renal insufficiency. Blaser J; Rüttimann S; Bhend H; Lüthy R Antimicrob Agents Chemother; 1983 Jun; 23(6):888-91. PubMed ID: 6614893 [TBL] [Abstract][Full Text] [Related]
18. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Conil JM; Georges B; Breden A; Segonds C; Lavit M; Seguin T; Coley N; Samii K; Chabanon G; Houin G; Saivin S Int J Antimicrob Agents; 2006 Sep; 28(3):226-30. PubMed ID: 16908121 [TBL] [Abstract][Full Text] [Related]
19. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of amikacin in patients with impaired renal function. McHenry MC; Wagner JG; Hall PM; Vidt DG; Gavan TL J Infect Dis; 1976 Nov; 134 SUPPL():S343-8. PubMed ID: 993627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]